Roche’s immunotherapy cancer drug given FDA approval

Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given FDA approval for treatment of metastatic non-small cell lung cancer. The figures released earlier this month showed that those taking the drug lived a median of 13.8 months, which worked out, on average, as 4.2 months longer than those being treated with chemotherapy.
read more http://www.pharmafile.com/news/510795/roche-s-immunotherapy-cancer-drug-given-fda-approval